

1 **Supplementary Table 1. Adjuvant chemotherapy regimens**

Variables		RFS < 2 years (n = 45)	RFS ≥ 2 years (n = 55)	<i>p</i>
Adjuvant therapy regimen	S-1	37	49	0.88
	Gemcitabine	2	3	
	GnP	1	0	
	Modified FOLFIRINOX	0	1	
	None	5	2	

2

3 GnP, gemcitabine plus nab-paclitaxel; FOLFIRINOX, fluorouracil, leucovorin, irinotecan, and oxaliplatin; RFS,
4 recurrence-free survival

5

6 **Supplementary Table 2. Sites of initial recurrence**

Site	n (%)
Liver	16 (35.6)
Lymph nodes	8 (17.8)
Lungs	7 (15.6)
Peritoneum	7 (15.6)
Locoregional areas	5 (11.1)
Bone	1 (2.2)
Subcutaneous	1 (2.2)

7

8

9 **Supplementary Table 3. Cox proportion hazards model for RFS**

Variable	HR	95% CI	<i>p</i>
Pre-NAC CA19-9	2.15	0.87–5.33	0.09
Post-NAC tumor size	1.22	0.53–2.84	0.64
Post-NAC CA19-9	0.85	0.35–2.08	0.72
Pathological tumor size	2.73	1.16–6.44	0.02
Positive lymph nodes (pN1)	1.60	0.70–3.67	0.27

10

11 HR, hazard ratio; CI, confidence interval; NAC, neoadjuvant chemotherapy; CA19-9, carbohydrate antigen 19-9

12

13